Don't miss a thing this May with this comprehensive list of holidays and happenings.

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

No other corporate actions details are available.